A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough (RELIEF)
A Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects With Unexplained or Refractory Chronic Cough (RELIEF)
Sponsor: Bellus Health Inc. - a GSK company
Terminated
Trial was terminated due to the impact of the COVID-19 on trial activities. 68 patients with refractory chronic cough were enrolled with 52 completing treatment
This PHASE2 trial investigates Chronic Refractory Cough and is currently terminated or withdrawn. Bellus Health Inc. - a GSK company leads this study, which shows 15 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jan 2024 [monthly]
Terminated PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 10 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2020 — Oct 2020 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2020 — May 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bellus Health Inc. - a GSK company
For direct contact, visit the study record on ClinicalTrials.gov .